The 3rd Precision Medicine in Inflammatory Bowel Disease Summit provided an unmatched opportunity to connect with senior decision-makers from the immunology, gastrointestinal, and precision medicine sectors, committed to advancing innovation and overcoming challenges in this dynamic field.
Our audience of 80+ senior key opinion leaders were actively pursuing partnerships in data management, AI/ML, technological innovation, multi-omics sequencing and analysis, biomarker development, and other cutting-edge services. They were eager to connect and collaborate with leading solution and service providers driving advancements in these fields.
Our Audience was Looking for:
Who Will You Meet?
AI / Bioinformatics / Computation Providers: Tools to analyze complex datasets, enhance patient stratification, and optimize precision medicine approaches
Diagnostics: Advanced technologies to drive biomarker development, improve disease monitoring, and enable targeted therapies
Omics: Multi-omics insights to uncover novel therapeutic targets and refine personalized treatment pathways
CROs: Expertise to streamline clinical trials, ensure regulatory compliance, and accelerate drug development
Why Partner?
Showcase Your Innovations to IBD Precision Medicine Leaders
Demonstrate your cutting-edge technologies and diagnostics to top decision-makers, gain strategic exposure, and forge key partnerships to drive better IBD outcomes.
Gain Strategic Market Insights to Stay Ahead in the Dynamic IBD Landscape
Steal competitive insights to align your solutions with biopharma priorities in patient stratification, disease monitoring and therapy development to remain a key partner in advancing IBD care.
Forge High-Impact Collaborations with Influential Stakeholders from Biopharma, Diagnostics, & Academic Institutions
Connect with biopharma, diagnostics and academia through targeted branding, ensuring you can maximize networking to drive innovation in IBD precision medicine and patient care.